Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Pedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaPedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie
Zmień bibliotekę

Wyszukujesz frazę "Sefah, Israel" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-6 z 6
    Tytuł:
    The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future
    Autorzy:
    Piloya-Were, Thereza
    Dias Godoi, Isabella Piassi
    Bae, SeungJin
    Jakovljevic, Mihajlo
    Nahar, Shamsun
    Njeri, Lisper Wangeci
    Tubic, Biljana
    Wale, Janney
    Khan, Tanveer Ahmed
    Abhayanand, Jha Pallavi
    Sani, Ibrahim Haruna
    Gambogi, Rosana
    Haque, Monami
    Jahan, Iffat
    Hernandez Ortiz, Carla
    Inotai, Andras
    Islam, Salequl
    Haque, Mainul
    Khan, M. A. Halim
    Incoom, Robert
    Zara, Corinne
    Hasin, Humaira
    Kumar, Santosh
    Petrova, Guenka
    Jakupi, Arianit
    Hoxha, Iris
    Abubakar, Abdullahi Rabiu
    Allocati, Eleonora
    Leong, Trudy
    Charan, Jaykaran
    Alam, A.B.M. Muksudul
    Kimonge, David
    McTaggart, Stuart
    Furst, Jurij
    Rwegerera, Godfrey Mutashambara
    Kwon, Hye-Young
    Khuan, Karen Koh Pek
    Hussain, Shahzad
    Deeba, Farzana
    Godman, Brian
    Murshid, Munzur E.
    Opanga, Sylvia
    Malande, Oliver Ombeva
    Laius, Ott
    Garuoliene, Kristina
    Akter, Farhana
    Gulbinovic, Jolanta
    Dutta, Siddhartha
    Bakar, Muhammed Abu
    Kamal, Zubair Mahmood
    Acharya, Jitendra
    Mardare, Ileana
    Pontes, Caridad
    Sultana, Nusrat
    Alutuli, Luke
    Saleem, Zikria
    MacBride-Stewart, Sean
    Irfan, Mohammed
    Harsanyi, Andras
    Henkuzens, Svens
    Rahim, Sagir Abdur
    Rutkowski, Jakub
    Sefah, Israel Abebrese
    Tagoe, Eunice Twumwaa
    do Nascimento, Renata Cristina Rezende Macedo
    Kaur, Rimple Jeet
    Tachkov, Konstantin
    Władysiuk, Magdalena
    Kurdi, Amanj
    Vassalo, Carlos
    Banzi, Rita
    Amu, Adefolarin A.
    Matowa, Patrick
    Acolatse, Joseph
    Markovic-Pekovic, Vanda
    Kalungia, Aubrey Chichonyi
    Opis:
    Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers. Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders. Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries. Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production. Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities.
    Dostawca treści:
    Repozytorium Uniwersytetu Jagiellońskiego
    Artykuł
      Wyświetlanie 1-6 z 6

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies